Med Drug Classes Neuro Endocrine Immunology And Oncology

---
name: med-drug-classes-neuro-endocrine-immunology-and-oncology
description: "Use for these drug classes specifically: neurological and psychiatric agents and the honest state of their mechanistic explanations, endocrine and metabolic therapy including diabetes and thyroid treatment, immunology and biologics with monoclonal antibodies and immunosuppression, and oncology across cytotoxic, targeted and immunotherapy approaches. Technical orientation, not medical advice."
---

# Medicine and Pharmacology: Neurological and Psychiatric, Endocrine and Metabolic, Immunology and Biologics, and Oncology

> **Part 4 of 6** of the *Fundamentals of Medicine and Pharmacology* reference (plugin `medicine-and-pharmacology-fundamentals`), covering §16–§19. Sibling skills: `med-reading-the-field-physiology-and-clinical-reasoning` (§0–§6), `med-pharmacokinetics-pharmacodynamics-and-interactions` (§7–§12), `med-drug-classes-cardiovascular-anti-infective-and-analgesia` (§13–§15), `med-evidence-trials-safety-screening-and-ethics` (§20–§26), `med-reference` (§27–§32). Section numbers are shared across the set; a reference written as §N → `skill` points into that sibling skill.
>
> **Currency:** The physiology and pharmacology are stable. Two areas are moving fast. See §27 → `med-reference` for incretin therapeutics, and antimicrobial resistance.

> **⚠️ NOT MEDICAL ADVICE, and this matters more here than in any other file in this
> series.** ⚠️ **Nothing here is a diagnosis, a treatment recommendation, or dosing
> guidance. Individual clinical decisions require a licensed clinician who knows your
> history, and no general reference substitutes for that.**
>
> **⚠️ This is pitched where a preclinical survey or an informed-patient reference sits:
> the concepts that let you understand what medicine is doing and evaluate claims about
> it.** ⚠️ **It deliberately contains no dosing tables, no specific regimens, and no
> operational detail.**
>
> **Complements an organic-chemistry reference (drug molecules and metabolism), a
> statistics-adjacent reference (trial methodology), and a speaking-and-influence reference
> (§20 → `med-evidence-trials-safety-screening-and-ethics`'s evidence-quality reasoning is the same skill).**
>
> **⚠️ GOTCHA** boxes mark where clinical intuition — including clinicians' intuition — is
> reliably wrong.
>
> **The three ideas that organize this document:**
> 1. **⚠️ A TEST RESULT IS NOT A DIAGNOSIS** (§6 → `med-reading-the-field-physiology-and-clinical-reasoning`). **The probability that a positive test
>    means disease depends on how likely disease was beforehand. This single Bayesian fact
>    is the most useful thing in clinical medicine and the most consistently misunderstood
>    by patients and clinicians alike.**
> 2. **⚠️ EVERY DRUG IS A POISON AT SOME DOSE, AND EVERY EFFECT HAS A COST** (§9 → `med-pharmacokinetics-pharmacodynamics-and-interactions`, §12 → `med-pharmacokinetics-pharmacodynamics-and-interactions`).
>    **There are no side effects — only effects, some of which you wanted. The therapeutic
>    question is always a ratio, never an absolute.**
> 3. **⚠️ MOST OF WHAT DETERMINES HEALTH HAPPENS OUTSIDE CLINICAL MEDICINE** (§25 → `med-evidence-trials-safety-screening-and-ethics`).
>    **Sanitation, nutrition, income, housing and vaccination did more for life expectancy
>    than the entire therapeutic pharmacopoeia, and clinical medicine's share of health
>    outcomes is smaller than its share of spending.**

---

## §16. Neurological and Psychiatric

**⚠️ The honest framing first**: ⚠️ **psychiatric drug mechanisms are less well understood
than marketing implies.** ⚠️ **The "chemical imbalance" account was always a simplification
and the simple monoamine-deficiency version is not supported; ⚠️ this does not mean the
drugs do not work — it means we do not fully know why they do.**
**⚠️ Antidepressants** (SSRIs, SNRIs, others): ⚠️ **the delay to effect of weeks, despite
immediate receptor occupancy, is itself evidence that the mechanism involves downstream
adaptation.** ⚠️ **Efficacy over placebo is real and modest on average, larger in severe
depression, and the debate about effect size is genuine.**
**⚠️ Antipsychotics** — ⚠️ **dopamine antagonism, with metabolic and movement-disorder
adverse effects that are substantial and often under-monitored.**
**⚠️ Anxiolytics** — ⚠️ **benzodiazepines are effective short term with dependence and
withdrawal risk that made long-term use inadvisable** (§8 → `med-pharmacokinetics-pharmacodynamics-and-interactions`'s upregulation).
**⚠️ Mood stabilizers, antiepileptics, and drugs for Parkinson's, dementia and migraine.**
**⚠️ Discontinuation** matters and is under-taught: ⚠️ **many of these require gradual
tapering, and withdrawal effects have historically been under-recognized in the
literature.**

---

## §17. Endocrine and Metabolic

**⚠️ The general logic**: ⚠️ **replace a deficient hormone, block an excessive one, or
modulate a receptor.**
**⚠️ Diabetes** — ⚠️ **insulin, metformin, sulfonylureas, SGLT2 inhibitors and incretins
(§27.1 → `med-reference`) — with the important development being that several agents are now chosen for
CARDIOVASCULAR AND RENAL outcome benefits rather than for glucose lowering alone, which
represents a genuine shift from surrogate to outcome endpoints** (§21 → `med-evidence-trials-safety-screening-and-ethics`).
**⚠️ Thyroid, adrenal and sex hormone therapies** — ⚠️ **and the HRT story is a cautionary
tale about how initial trial reporting, subsequent reanalysis by age group, and public
communication interacted badly, leaving lasting confusion.**
**⚠️ Corticosteroids** are extraordinarily useful and extraordinarily consequential:
⚠️ **broad anti-inflammatory effect, with adrenal suppression on withdrawal, and a long
list of effects with prolonged use.**
**⚠️ Bone, obesity and lipid agents** — ⚠️ **and see §27.1 → `med-reference` for the class currently reshaping
this area.**

---

## §18. Immunology and Biologics

**⚠️ The immune system in one paragraph**: ⚠️ **innate (fast, non-specific) and adaptive
(slow, specific, memory — which is what vaccination exploits), with tolerance mechanisms
that prevent attacking self and whose failure is autoimmunity.**
**⚠️ BIOLOGICS** are large, complex molecules — ⚠️ **usually proteins, made in living cells,
which means they must be injected (§7 → `med-pharmacokinetics-pharmacodynamics-and-interactions`'s first-pass problem), can provoke immune responses
against themselves, and are expensive to manufacture.**
**⚠️ Monoclonal antibodies** are the dominant format — ⚠️ **and the naming convention encodes
the source (-ximab chimeric, -zumab humanized, -umab fully human), which is a useful thing
to be able to read.**
**⚠️ BIOSIMILARS are not generics**: ⚠️ **you cannot make an identical copy of a large
protein made in cells, so the regulatory pathway requires demonstrating similarity rather
than identity — which is why they cost more and arrive slower than small-molecule
generics.**
**⚠️ Immunosuppression's central trade**: ⚠️ **suppressing an overactive immune response
necessarily increases infection and malignancy risk, and this trade cannot be engineered
away entirely.**

---

## §19. Oncology

**⚠️ Cancer is many diseases**, ⚠️ **unified by the hallmarks framework — sustained
proliferative signalling, evasion of growth suppression and apoptosis, replicative
immortality, angiogenesis, invasion and metastasis, immune evasion and altered metabolism.**
**⚠️ Conventional cytotoxic chemotherapy** targets rapidly dividing cells — ⚠️ **which is
why its adverse effects fall on bone marrow, gut lining and hair follicles, and why its
therapeutic index is narrow** (§9 → `med-pharmacokinetics-pharmacodynamics-and-interactions`).
**⚠️ TARGETED THERAPY** exploits a specific molecular lesion; ⚠️ **it works impressively
where a driver mutation exists, and RESISTANCE typically emerges through alternative
pathways.**
**⚠️ IMMUNOTHERAPY** — ⚠️ **checkpoint inhibitors release the brakes on the immune system,
producing durable responses in a minority of patients and a distinctive set of autoimmune
adverse effects; CAR-T for certain haematological cancers.**
> **⚠️ GOTCHA — cancer survival statistics are systematically distorted by two biases that
> screening introduces** (§24 → `med-evidence-trials-safety-screening-and-ethics`). ⚠️ **LEAD TIME bias makes earlier diagnosis increase measured
> survival even if death occurs at the same moment; ⚠️ LENGTH bias means screening
> preferentially detects slow-growing tumours with better prognosis.** **⚠️ Five-year
> survival is therefore a poor measure of whether an intervention helps; MORTALITY is the
> honest endpoint.**

---

# PART IV — THE SYSTEM